Literature DB >> 18202893

Inclusion of tumor markers improves the correlation of the Milan criteria with vascular invasion and tumor cell differentiation in patients with hepatocellular carcinoma undergoing liver resection (#JGSU-D-07-00462).

Kiyoshi Hasegawa1, Hiroshi Imamura, Masayoshi Ijichi, Yutaka Matsuyama, Keiji Sano, Yasuhiko Sugawara, Norihiro Kokudo, Masatoshi Makuuchi.   

Abstract

The currently used criteria, such as the Milan criteria, to select a candidate of liver transplantation for HCC consists of size and number of tumors because vascular invasion and poor differentiation, the strongest prognostic factors, are difficult to be assessed preoperatively. We hypothesized that inclusion of two tumor markers (alpha-fetoprotein and des-gamma-carboxy prothrombin) into the criteria would increase the prediction accuracy of these factors. Our hypothesis was tested in 478 HCC patients undergoing liver resection. The models with or without markers, constructed at predicting vascular invasion (n=150) or poor differentiation (n=49), were compared. The model including markers was superior at predicting the absence of vascular invasion to either the Milan criteria alone [at 81.2% sensitivity; specificity, 52.4 vs 43.3%; difference, 9.1%(95% CI, 1.3-14.2%)] or a model in which size and number varied freely [AUCs of receiver operating characteristic curves, 75.2 vs 69.1%; difference, 6.1%(2.33-10.7%)]. The model incorporating markers was also superior at predicting well to moderate differentiation to either the Milan criteria [at 74.5% sensitivity; specificity, 57.1 vs 38.8%; difference, 18.3%(2.4-32.7%)] or a model with size and number [AUCs, 71.5 vs 59.0%; difference, 12.5%(5.84-21.4%)]. In conclusion, the tumor marker levels should be considered when selecting patients with HCC for liver transplantation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18202893     DOI: 10.1007/s11605-007-0464-9

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  53 in total

1.  The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin.

Authors:  G L Grazi; A Mazziotti; C Legnani; E Jovine; R Miniero; A Gallucci; G Palareti; G Gozzetti
Journal:  Liver Transpl Surg       Date:  1995-07

2.  Clinical usefulness of des-gamma-carboxy prothrombin assay in early diagnosis of hepatocellular carcinoma.

Authors:  S Fujiyama; K Izuno; K Gohshi; J Shibata; T Sato
Journal:  Dig Dis Sci       Date:  1991-12       Impact factor: 3.199

Review 3.  Pathologic characteristics of hepatocellular carcinoma.

Authors:  T Nakashima; M Kojiro
Journal:  Semin Liver Dis       Date:  1986-08       Impact factor: 6.115

Review 4.  Newer markers for hepatocellular carcinoma.

Authors:  Jorge A Marrero; Anna S F Lok
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

5.  Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma.

Authors:  T J Tsai; G Y Chau; W Y Lui; S H Tsay; K L King; C C Loong; C Y Hsia; C W Wu
Journal:  Surgery       Date:  2000-06       Impact factor: 3.982

6.  Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multicenter study.

Authors:  J Figueras; L Ibañez; E Ramos; E Jaurrieta; J Ortiz-de-Urbina; F Pardo; J Mir; C Loinaz; L Herrera; P López-Cillero; J Santoyo
Journal:  Liver Transpl       Date:  2001-10       Impact factor: 5.799

7.  Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study.

Authors:  Jessica Y Leung; Andrew X Zhu; Fredric D Gordon; Daniel S Pratt; Abigail Mithoefer; Kathryn Garrigan; Adam Terella; Martin Hertl; A Benedict Cosimi; Raymond T Chung
Journal:  Liver Transpl       Date:  2004-11       Impact factor: 5.799

8.  Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis.

Authors:  S Jonas; W O Bechstein; T Steinmüller; M Herrmann; C Radke; T Berg; U Settmacher; P Neuhaus
Journal:  Hepatology       Date:  2001-05       Impact factor: 17.425

Review 9.  Resection and liver transplantation for hepatocellular carcinoma.

Authors:  Josep M Llovet; Myron Schwartz; Vincenzo Mazzaferro
Journal:  Semin Liver Dis       Date:  2005       Impact factor: 6.115

10.  Liver transplantation for hepatocellular carcinoma: the MELD impact.

Authors:  Pratima Sharma; Vijayan Balan; Jose L Hernandez; Ann M Harper; Erick B Edwards; Hector Rodriguez-Luna; Thomas Byrne; Hugo E Vargas; David Mulligan; Jorge Rakela; Russell H Wiesner
Journal:  Liver Transpl       Date:  2004-01       Impact factor: 5.799

View more
  4 in total

1.  Differential effects of vitamin K1 on AFP and DCP levels in patients with unresectable HCC and in HCC cell lines.

Authors:  Brian I Carr; Ziqiu Wang; Meifung Wang; Gang Wei
Journal:  Dig Dis Sci       Date:  2010-12-28       Impact factor: 3.199

2.  AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC.

Authors:  Kentaroh Yamamoto; Hiroshi Imamura; Yutaka Matsuyama; Yukio Kume; Hitoshi Ikeda; Gary L Norman; Zakera Shums; Taku Aoki; Kiyoshi Hasegawa; Yoshifumi Beck; Yasuhiko Sugawara; Norihiro Kokudo
Journal:  J Gastroenterol       Date:  2010-07-13       Impact factor: 7.527

3.  Propensity score analysis demonstrated the prognostic advantage of anatomical liver resection in hepatocellular carcinoma.

Authors:  Masayuki Ishii; Toru Mizuguchi; Masaki Kawamoto; Makoto Meguro; Shigenori Ota; Toshihiko Nishidate; Kenji Okita; Yasutohsi Kimura; Thomas T Hui; Koichi Hirata
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

4.  Frequency of and predictive factors for vascular invasion after radiofrequency ablation for hepatocellular carcinoma.

Authors:  Yoshinari Asaoka; Ryosuke Tateishi; Ryo Nakagomi; Mayuko Kondo; Naoto Fujiwara; Tatsuya Minami; Masaya Sato; Koji Uchino; Kenichiro Enooku; Hayato Nakagawa; Yuji Kondo; Shuichiro Shiina; Haruhiko Yoshida; Kazuhiko Koike
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.